SLV logo

Selvita Stock Price

Symbol: WSE:SLVMarket Cap: zł578.2mCategory: Pharmaceuticals & Biotech

SLV Share Price Performance

zł31.10
-35.40 (-53.23%)
zł31.10
-35.40 (-53.23%)
Price zł31.10

SLV Community Narratives

There are no narratives available yet.

Recent SLV News & Updates

Selvita S.A. (WSE:SLV) Stock Catapults 25% Though Its Price And Business Still Lag The Industry

Jul 25
Selvita S.A. (WSE:SLV) Stock Catapults 25% Though Its Price And Business Still Lag The Industry

A Piece Of The Puzzle Missing From Selvita S.A.'s (WSE:SLV) 28% Share Price Climb

May 14
A Piece Of The Puzzle Missing From Selvita S.A.'s (WSE:SLV) 28% Share Price Climb

Is Selvita (WSE:SLV) Using Too Much Debt?

Apr 29
Is Selvita (WSE:SLV) Using Too Much Debt?

Selvita S.A. Key Details

zł359.8m

Revenue

zł74.9m

Cost of Revenue

zł284.9m

Gross Profit

zł289.8m

Other Expenses

-zł4.9m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Sep 18, 2025
Earnings per share (EPS)
-0.27
Gross Margin
79.18%
Net Profit Margin
-1.38%
Debt/Equity Ratio
32.4%

Selvita S.A. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Very undervalued with reasonable growth potential.

0 Risks
4 Rewards

About SLV

Founded
2007
Employees
969
CEO
Boguslaw Sieczkowski
WebsiteView website
selvita.com

Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology. It also develops drugs for therapeutic areas, such as oncology, infectious diseases, immunology, neurology, respiratory, and other. In addition, the company provides drug development services, including formulation development; CMC analytical support; stability and shelf-life determination; clinical supply/GMP manufacturing; small molecules bioanalysis; drug substance and product; and biologics and biosimilars bioanalysis services. Further, it offers research and development services in the areas of agrochemistry analytical support, and flavor and fragrance chemistry. The company was formerly known as Selvita CRO S.A. and changed its name to Selvita S.A. in October 2019. Selvita S.A. was founded in 2007 and is based in Kraków, Poland.

Market Insight

The number of IPOs and the capital raised this year are on track to outpace the last three years combined. And the thing is, successful IPOs attract more IPOs. Some will be genuine gems, while others, not so much. That’s why this week, we’re digging into the IPO market, and more importantly, how you can improve your odds of spotting a winner.
Continue reading

Polish Market Performance

  • 7 Days: -5.4%
  • 3 Months: 1.9%
  • 1 Year: 18.5%
  • Year to Date: 25.6%
Over the last 7 days, the market has dropped 5.4%, driven by a decline of 9.0% in the Financials sector. In contrast to the last week, the market is actually up 18% over the past year. Looking forward, earnings are forecast to grow by 14% annually. Market details ›